JP2022522996A5 - - Google Patents

Info

Publication number
JP2022522996A5
JP2022522996A5 JP2021541524A JP2021541524A JP2022522996A5 JP 2022522996 A5 JP2022522996 A5 JP 2022522996A5 JP 2021541524 A JP2021541524 A JP 2021541524A JP 2021541524 A JP2021541524 A JP 2021541524A JP 2022522996 A5 JP2022522996 A5 JP 2022522996A5
Authority
JP
Japan
Prior art keywords
sequence
pharmaceutical composition
composition according
polynucleotide
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021541524A
Other languages
English (en)
Japanese (ja)
Other versions
JP7595013B2 (ja
JP2022522996A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/051283 external-priority patent/WO2020148458A1/en
Publication of JP2022522996A publication Critical patent/JP2022522996A/ja
Publication of JP2022522996A5 publication Critical patent/JP2022522996A5/ja
Priority to JP2024204975A priority Critical patent/JP2025032155A/ja
Application granted granted Critical
Publication of JP7595013B2 publication Critical patent/JP7595013B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021541524A 2019-01-18 2020-01-20 オトフェリン遺伝子を回復させるaav媒介遺伝子治療 Active JP7595013B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024204975A JP2025032155A (ja) 2019-01-18 2024-11-25 オトフェリン遺伝子を回復させるaav媒介遺伝子治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19305071 2019-01-18
EP19305071.3 2019-01-18
PCT/EP2020/051283 WO2020148458A1 (en) 2019-01-18 2020-01-20 Aav-mediated gene therapy restoring the otoferlin gene

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024204975A Division JP2025032155A (ja) 2019-01-18 2024-11-25 オトフェリン遺伝子を回復させるaav媒介遺伝子治療

Publications (3)

Publication Number Publication Date
JP2022522996A JP2022522996A (ja) 2022-04-21
JP2022522996A5 true JP2022522996A5 (cg-RX-API-DMAC7.html) 2024-05-10
JP7595013B2 JP7595013B2 (ja) 2024-12-05

Family

ID=65351986

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021541524A Active JP7595013B2 (ja) 2019-01-18 2020-01-20 オトフェリン遺伝子を回復させるaav媒介遺伝子治療
JP2024204975A Pending JP2025032155A (ja) 2019-01-18 2024-11-25 オトフェリン遺伝子を回復させるaav媒介遺伝子治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024204975A Pending JP2025032155A (ja) 2019-01-18 2024-11-25 オトフェリン遺伝子を回復させるaav媒介遺伝子治療

Country Status (22)

Country Link
US (1) US20220125875A1 (cg-RX-API-DMAC7.html)
EP (2) EP4295913A3 (cg-RX-API-DMAC7.html)
JP (2) JP7595013B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260046255A (cg-RX-API-DMAC7.html)
CN (1) CN113924109A (cg-RX-API-DMAC7.html)
AU (2) AU2020208933B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021013996A2 (cg-RX-API-DMAC7.html)
CA (1) CA3126884A1 (cg-RX-API-DMAC7.html)
DK (1) DK3911354T5 (cg-RX-API-DMAC7.html)
ES (1) ES2960880T3 (cg-RX-API-DMAC7.html)
FI (1) FI3911354T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20231296T1 (cg-RX-API-DMAC7.html)
HU (1) HUE063458T2 (cg-RX-API-DMAC7.html)
IL (1) IL284742B2 (cg-RX-API-DMAC7.html)
LT (1) LT3911354T (cg-RX-API-DMAC7.html)
MX (1) MX2021008622A (cg-RX-API-DMAC7.html)
PL (1) PL3911354T3 (cg-RX-API-DMAC7.html)
PT (1) PT3911354T (cg-RX-API-DMAC7.html)
RS (1) RS64794B1 (cg-RX-API-DMAC7.html)
SI (1) SI3911354T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300359T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020148458A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12359221B2 (en) 2017-05-05 2025-07-15 The Regents Of The University Of California Compositions and methods for expressing otoferlin
IL325122A (en) 2018-02-22 2026-02-01 Akouos Inc Compositions and methods for treating non-age-related hearing impairment in humans
US11660353B2 (en) 2018-04-27 2023-05-30 Decibel Therapeutics, Inc. Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
CN112703016B (zh) 2018-04-27 2024-11-22 分贝治疗公司 肌球蛋白15启动子及其用途
WO2020163761A1 (en) 2019-02-08 2020-08-13 Decibel Therapeutics, Inc. Myosin 15 promoters and uses thereof
EP3921032A4 (en) 2019-02-08 2022-11-30 Decibel Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF SENSORINEURAL HEARING LOSS USING OTOFERLIN DOUBLE VECTOR SYSTEMS
TWI896570B (zh) 2019-10-30 2025-09-11 美商迪賽博治療公司 使用耳畸蛋白雙載體系統治療感覺神經性聽力損失之組合物及方法
CA3168055A1 (en) 2020-02-21 2021-08-26 Emmanuel John Simons Compositions and methods for treating non-age-associated hearing impairment in a human subject
IL295741A (en) 2020-04-01 2022-10-01 Univ Florida Dual aav-myo7a vectors with improved safety for the treatment of ush1b
MX2023005344A (es) * 2020-11-06 2023-12-07 Lilly Co Eli Polipéptidos de la cápside variante del virus adenoasociado (aav) y su terapéutico génica para el tratamiento de la pérdida de audición.
KR20240004253A (ko) * 2021-02-19 2024-01-11 데시벨 테라퓨틱스, 인크. 오토펄린 듀얼 벡터 시스템을 사용한 감각신경성 난청을 치료하기 위한 방법
JP2024534991A (ja) * 2021-09-10 2024-09-26 インスティチュート パスツール オトフェリンのアイソフォーム5をコードする二重組換えaav8ベクター系およびその使用
CN117106824B (zh) * 2022-05-17 2025-09-02 上海佑音医药生物科技有限公司 一种治疗听力损伤的双载体系统及其应用
CN116606885A (zh) * 2023-02-21 2023-08-18 东南大学 一种Lhfpl5基因敲除鼠构建实验方法
CN116925239B (zh) * 2023-07-17 2024-10-18 苏州星奥拓维生物技术有限公司 双载体系统表达Otof基因的组合物和方法
CN117305367A (zh) * 2023-08-21 2023-12-29 复旦大学附属眼耳鼻喉科医院 一种表达全长耳畸蛋白的双aav载体系统及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
AU2003209226A1 (en) 2002-01-11 2003-07-30 Michael Tennant Adiponectin gene therapy
WO2006036465A2 (en) 2004-09-03 2006-04-06 University Of Florida Compositions and methods for treating cystic fibrosis
US8298818B2 (en) 2006-04-28 2012-10-30 University Of Florida Research Foundation, Inc. Self-complementary adeno-associated virus having a truncated CMV-chicken β-actin promoter
WO2011075838A1 (en) 2009-12-21 2011-06-30 Audigen Inc. Method of treating or preventing hearing loss
WO2013075008A1 (en) 2011-11-16 2013-05-23 University Of Florida Research Foundation Inc. Aav dual vector systems for gene therapy
KR102298579B1 (ko) * 2013-05-21 2021-09-07 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 캡시드-변형된 raav3 벡터 조성물, 및 인간 간암의 유전자 요법에서의 용도
US10751385B2 (en) * 2015-02-20 2020-08-25 Institut Pasteur Prevention and/or treatment of hearing loss or impairment
CA3007476A1 (en) 2015-12-11 2017-06-15 Massachusetts Eye And Ear Infirmary Materials and methods for delivering nucleic acids to cochlear and vestibular cells
WO2018039375A1 (en) * 2016-08-23 2018-03-01 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
US12359221B2 (en) * 2017-05-05 2025-07-15 The Regents Of The University Of California Compositions and methods for expressing otoferlin
IL325122A (en) * 2018-02-22 2026-02-01 Akouos Inc Compositions and methods for treating non-age-related hearing impairment in humans
US11660353B2 (en) * 2018-04-27 2023-05-30 Decibel Therapeutics, Inc. Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
TWI896570B (zh) 2019-10-30 2025-09-11 美商迪賽博治療公司 使用耳畸蛋白雙載體系統治療感覺神經性聽力損失之組合物及方法

Similar Documents

Publication Publication Date Title
FI3911354T3 (fi) Otoferliinigeenin palauttava AAV-välitteinen geeniterapia
CN111607002B (zh) 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白双区域亚单位纳米疫苗
JP2023070682A5 (cg-RX-API-DMAC7.html)
JP2022554300A5 (cg-RX-API-DMAC7.html)
CN113316639A (zh) 用于治疗庞贝氏病的治疗性腺相关病毒
JP2023503637A5 (cg-RX-API-DMAC7.html)
JP2020510428A5 (cg-RX-API-DMAC7.html)
JP2020518268A5 (cg-RX-API-DMAC7.html)
JP2023504773A5 (cg-RX-API-DMAC7.html)
JP2022513308A5 (cg-RX-API-DMAC7.html)
EP4527933A1 (en) Dual-carrier system for treating hearing damage, and use thereof
RU2005136233A (ru) Выделенный рекомбинантный вирус гриппа и способы его получения
JP2024534991A5 (cg-RX-API-DMAC7.html)
JP2023520488A5 (cg-RX-API-DMAC7.html)
JP2021533805A5 (cg-RX-API-DMAC7.html)
KR20220092583A (ko) 인자 viii 폴리펩타이드
RU2019126509A (ru) Выделенный модифицированный белок VP1 капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе
RU2019103488A (ru) Способы и композиции для лечения нарушений и заболеваний, связанных с rdh12
JP2023535121A5 (cg-RX-API-DMAC7.html)
AU2020257570A1 (en) Gene therapy of fibroblast growth factor 23 related hypophosphatemic diseases
KR20210158859A (ko) Ube3a 유전자 및 발현 카세트 및 이들의 용도
CN113574176A (zh) 腺相关病毒对cln6多核苷酸的递送
JP2024515902A5 (cg-RX-API-DMAC7.html)
EP3185909B1 (en) Methods and compositions for treating leber congenital amaurosis
US20220389450A1 (en) Vector system